Targeted therapy for pancreatic cancer is reliable and can effectively prolong the survival period. Pancreatic cancer is a malignant tumor of digestive system. Targeted therapy can target specific gene mutation of tumor cells or key steps in the process of proliferation and infiltration to inhibit the growth of tumor cells, which can effectively prolong the survival cycle of pancreatic cancer, with good safety and efficiency. Targeted drugs for pancreatic cancer include trastuzumab, apatinib, and erlotinib, etc. After standardized use of these drugs, the survival cycle of patients can be extended for about half a year, but drug resistance can also occur, and the therapeutic effect of a single targeted drug is limited, so it is mostly recommended to carry out combined treatment with surgery, radiotherapy, chemotherapy, immunotherapy and so on. Targeted drugs can only be used if there is a corresponding target point, and targeted examinations should be done before using the drugs. Drugs should be used under the guidance of a doctor, do not use drugs blindly.